Kimelman & Baird’s Guardant Health GH Stock Holding History

Kimelman & Baird’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$285K	Hold	1,900	–	–	0.02%	106
2026 Q1	$176K	Hold	1,900	–	–	0.01%	116
2025 Q4	$194K	Hold	1,900	–	–	0.01%	115
2025 Q3	$119K	Hold	1,900	–	–	0.01%	138
2025 Q2	$98.9K	Hold	1,900	–	–	0.01%	147
2025 Q1	$80.9K	Hold	1,900	–	–	0.01%	158
2024 Q4	$58K	Buy	+1,900	New	+$53.5K	﹤0.01%	173

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Kimelman & Baird's GH Position: Q2 2026 in Review

Kimelman & Baird held its Guardant Health (GH) position steady in Q2 2026 at 1,900 shares worth $285K. The position accounts for 0.02% of the portfolio, ranked #106.

Kimelman & Baird first reported a position in GH in Q4 2024 and has held it in 7 quarters since. 598 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Kimelman & Baird held 1,900 shares of Guardant Health worth $285K as of Q2 2026.
Kimelman & Baird left its Guardant Health share count unchanged in Q2 2026.
Guardant Health made up 0.02% of Kimelman & Baird's portfolio in Q2 2026, its #106 holding.
Kimelman & Baird first reported a position in Guardant Health in Q4 2024 and has held it in 7 quarters since.
598 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Kimelman & Baird's 13F filing for Q2 2026, filed 5 Aug 2026.